How to buy Clinigen Group shares | 629p

Own Clinigen Group shares in just a few minutes.

Posted

Fact checked

Clinigen Group plc is a medical distribution business based in the UK. Clinigen Group shares (CLIN.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 629p – an increase of 1.04% over the previous week. Clinigen Group employs 1,150 staff and has a trailing 12-month revenue of around £504.3 million.

How to buy shares in Clinigen Group

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: CLIN in this case.
  5. Research Clinigen Group shares. The platform should provide the latest information available.
  6. Buy your Clinigen Group shares. It's that simple.
The whole process can take as little as 15 minutes.

How has Coronavirus impacted Clinigen Group's share price?

Since the stock market crash in March caused by coronavirus, Clinigen Group's share price has had significant negative movement.

Its last market close was 629p, which is 28.11% down on its pre-crash value of 875p and 79.51% up on the lowest point reached during the March crash when the shares fell as low as 350.4p.

If you had bought £1,000 worth of Clinigen Group shares at the start of February 2020, those shares would have been worth £416.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £660.01.

Clinigen Group share price

Use our graph to track the performance of CLIN stocks over time.

Clinigen Group shares at a glance

Information last updated 2020-12-27.
Latest market close629p
52-week range347.2992p - 986.0158p
50-day moving average 652.6177p
200-day moving average 688.1303p
Wall St. target price1259.67p
PE ratio 66.4706
Dividend yield 0.08p (1.12%)
Earnings per share (TTM) 10.2p
Promoted
eToro Free Stocks

Invest in Clinigen Group shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Clinigen Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Clinigen Group price performance over time

Historical closes compared with the last close of 695p

1 week (2021-01-15) -2.11%
1 month (2020-12-22) 5.06%
3 months (2020-10-22) 21.93%
6 months (2020-07-22) -7.58%
1 year (2020-01-22) -29.58%
2 years (2019-01-22) -9.27%
3 years (2018-01-22) -36.70%
5 years (2016-01-22) 14.78%

Is Clinigen Group under- or over-valued?

Valuing Clinigen Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinigen Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clinigen Group's P/E ratio

Clinigen Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Clinigen Group shares trade at around 66x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Clinigen Group's EBITDA

Clinigen Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £122.6 million.

The EBITDA is a measure of a Clinigen Group's overall financial performance and is widely used to measure a its profitability.

Clinigen Group financials

Revenue TTM £504.3 million
Operating margin TTM 14.65%
Gross profit TTM £220 million
Return on assets TTM 4.18%
Return on equity TTM 3.1%
Profit margin 2.72%
Book value 3.355p
Market capitalisation £901.9 million

TTM: trailing 12 months

Clinigen Group share dividends

68%

Dividend payout ratio: 67.65% of net profits

Recently Clinigen Group has paid out, on average, around 67.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinigen Group shareholders could enjoy a 1.12% return on their shares, in the form of dividend payments. In Clinigen Group's case, that would currently equate to about 0.08p per share.

Clinigen Group's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 5 November 2020 (the "ex-dividend date").

Clinigen Group share price volatility

Over the last 12 months, Clinigen Group's shares have ranged in value from as little as 347.2992p up to 986.0158p. A popular way to gauge a stock's volatility is its "beta".

CLIN.LSE volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Clinigen Group's is 1.1344. This would suggest that Clinigen Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Clinigen Group overview

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Frequently asked questions

More guides on Finder

  • How to buy Clinigen Group shares

    Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Charlie’s Holdings shares

    Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Lemonade shares | $50.05

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Unity Software shares | $111.51

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares | $3.745

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Clinigen Group shares | $0.1275

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares | $0.93

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares | $4.66

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

  • How to buy Xeros Technology Group shares | 220p

    Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.

  • How to buy Xpediator shares | 33.5p

    Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site